1. Home
  2. Share Market
  3. Stocks
  4. Bliss GVS Pharma
  5. Financial Statements
  6. Key Financial Ratios

BLISSGVS Financial Statements

Bliss GVS Pharma Key Financial Ratios

Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar Mar-2021 Mar-2020 Mar-2018 Mar-2017
Growth matrix (%)        
Revenue growth (16) (15) 2.03 46
Op profit growth (13) (37) (2.80) 30.20
EBIT growth (26) (27) 3.69 17
Net profit growth (30) 65.50 (28) (0.50)
Profitability ratios (%)        
OPM 18.50 17.90 24.20 25.40
EBIT margin 19 21.40 24.80 24.40
Net profit margin 11.90 14.10 7.22 10.30
RoCE 11.90 18.90 27.70 28.40
RoNW 2.22 3.82 2.87 4.56
RoA 1.86 3.12 2.01 2.99
Per share ratios ()        
EPS 7.17 9.23 8.60 10.90
Dividend per share 0.50 0.50 1 0.60
Cash EPS 4.97 8.21 3.63 6
Book value per share 78.40 71.30 52 47.20
Valuation ratios        
P/E 13.80 10.90 22.70 16.20
P/CEPS 19.90 12.30 53.90 29.40
P/B 1.26 1.41 3.76 3.74
EV/EBIDTA 7.85 6.63 9.14 8.80
Payout (%)        
Dividend payout -- -- 17.50 7.54
Tax payout (29) (24) (32) (36)
Liquidity ratios        
Debtor days 320 224 124 127
Inventory days 55.60 36 24.30 20.10
Creditor days (68) (49) (59) (79)
Leverage ratios        
Interest coverage (20) (27) (8.90) (9.90)
Net debt / equity -- 0.03 0.05 0.15
Net debt / op. profit (0.20) 0.19 0.15 0.37
Cost breakup ()        
Material costs (57) (64) (48) (45)
Employee costs (12) (7.80) (8.50) (7.70)
Other costs (13) (11) (19) (22)
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar( In .Cr) Mar-2021 Mar-2020 Mar-2018 Mar-2017
Revenue 577 689 815 798
yoy growth (%) (16) (15) 2.03 46
Raw materials (329) (440) (391) (359)
As % of sales 57 63.80 48 44.90
Employee costs (68) (54) (69) (61)
As % of sales 11.80 7.79 8.50 7.68
Other costs (74) (72) (157) (176)
As % of sales 12.70 10.50 19.30 22
Operating profit 107 123 197 203
OPM 18.50 17.90 24.20 25.40
Depreciation (17) (13) (21) (20)
Interest expense (5.50) (5.40) (23) (20)
Other income 20.20 37.10 26.50 12.50
Profit before tax 104 142 179 175
Taxes (30) (34) (57) (63)
Tax rate (29) (24) (32) (36)
Minorities and other (5.50) 2.01 (30) (31)
Adj. profit 68.50 111 93 82
Exceptional items -- (13) (34) --
Net profit 68.50 97.30 58.80 82
yoy growth (%) (30) 65.50 (28) (0.50)
NPM 11.90 14.10 7.22 10.30
Switch to
Tabular Data
Graph
Y/e 31 Mar ( In .Cr) Mar-2021 Mar-2020 Mar-2018 Mar-2017
Profit before tax 104 142 179 175
Depreciation (17) (13) (21) (20)
Tax paid (30) (34) (57) (63)
Working capital 531 467 300 82.10
Other operating items -- -- -- --
Operating cashflow 587 563 401 175
Capital expenditure 245 212 (42) 65.20
Free cash flow 832 775 359 240
Equity raised 886 828 725 677
Investments 0.01 (0.80) 0.01 0.18
Debt financing/disposal 116 91.50 (4.80) 133
Dividends paid -- -- 10.30 6.19
Other items -- -- -- --
Net in cash 1,834 1,694 1,089 1,056
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar ( In .Cr) Mar-2021 Mar-2020 Mar-2019 Mar-2018
Equity capital 10.30 10.30 10.30 10.30
Preference capital -- -- -- --
Reserves 798 725 636 526
Net worth 808 736 646 536
Minority interest
Debt 122 126 102 118
Deferred tax liabilities (net) 11.80 7.13 4.54 10.70
Total liabilities 962 884 766 676
Fixed assets 237 242 192 143
Intangible assets
Investments 0.01 0.02 0.02 0.02
Deferred tax asset (net) 3.59 3.57 0.96 5.65
Net working capital 577 535 466 439
Inventories 98.90 76.90 77.40 59
Inventory Days 62.60 40.70 -- 26.40
Sundry debtors 464 548 461 298
Debtor days 293 290 -- 134
Other current assets 133 60.20 67.70 270
Sundry creditors (80) (94) (93) (59)
Creditor days 50.70 49.90 -- 26.30
Other current liabilities (39) (56) (47) (131)
Cash 145 103 107 88.90
Total assets 962 884 766 676
Switch to
Consolidated
Standalone


Particulars ( Rupees In Crores.) Mar-2022 Dec-2021 Sep-2021 Jun-2021 Mar-2021
Gross Sales 167 216 196 168 132
Excise Duty -- -- -- -- --
Net Sales 167 216 196 168 132
Other Operating Income -- -- -- -- --
Other Income 12.20 6.04 5.45 7.82 6.33
Total Income 179 222 201 176 138
Total Expenditure ** 147 256 167 134 115
PBIDT 32.40 (33) 34.90 42.40 23.20
Interest 1.63 1.04 0.68 1.40 2.36
PBDT 30.70 (34) 34.20 41 20.90
Depreciation 4.27 4.43 4.30 4.33 4.27
Minority Interest Before NP -- -- -- -- --
Tax 2.03 12.20 12 9.57 7.91
Deferred Tax 0.96 (2.60) (4.10) 0.99 0.52
Reported Profit After Tax 23.50 (49) 22.10 26.10 8.15
Minority Interest After NP 3.83 1.58 0.79 1.88 1.91
Net Profit after Minority Interest 19.60 (50) 21.30 24.30 6.24
Extra-ordinary Items -- (61) -- -- --
Adjusted Profit After Extra-ordinary item 19.60 11.30 21.30 24.30 6.24
EPS (Unit Curr.) 1.90 (4.80) 2.05 2.35 0.61
Book Value (Unit Curr.) -- -- -- -- --
Dividend (%) -- -- -- -- --
Equity 10.40 10.40 10.40 10.30 10.30
Public Shareholding (Number) -- -- -- -- --
Public Shareholding (%) -- -- -- -- --
Pledged/Encumbered - No. of Shares -- -- -- -- --
Pledged/Encumbered - % in Total Promoters Holding -- -- -- -- --
Pledged/Encumbered - % in Total Equity -- -- -- -- --
Non Encumbered - No. of Shares -- -- -- -- --
Non Encumbered - % in Total Promoters Holding -- -- -- -- --
Non Encumbered - % in Total Equity -- -- -- -- --
PBIDTM(%) 19.40 (15) 17.80 25.20 17.60
PBDTM(%) 18.40 (16) 17.40 24.40 15.80
PATM(%) 14 (22) 11.30 15.50 6.17

QuickLinks for Bliss GVS Pharma Ltd.

BLISSGVS News

BLISSGVS Information

BLISSGVS Financials

BLISSGVS Documents

Open ZERO Brokerage Demat Account
Open Demat Account

  • ₹0

    Per Order for ETF & Mutual Funds Brokerage

  • ₹20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity